Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) ...

Abbott will be trying its hand in the growing field of intravascular lithotripsy, with a clinical study to examine an unnamed ...

James Fujimoto is one of the pioneers of optical coherence tomography, which has revolutionized ... and to guide interventional treatment. Intravascular OCT was pioneered by one of Fujimoto ...

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to ...

Abbott ABT has received the FDA’s investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (“IVL”) system to evaluate the treatment of severe calcification in coronary ...

• Gharaibeh, Y., Lee, J., Zimin, V., Chaitanya, K., Dallan, L., Pereira, G. T. R., Vergara-Martel, A . . . Wilson, D. (2023). Prediction of Stent Under-Expansion in ...

They have created a novel contrast agent for intravascular optical coherence tomography (IV-OCT), a medical imaging technique. The new agent, derived from gold superclusters (AuSC), could assist ...